Evidence map›Paper›PMID 34800542›Full record

ArticleExperimental cell research2021

PLEKHA7 signaling is necessary for the growth of mutant KRAS driven colorectal cancer.

Hei-Cheul Jeung, Roisin Puentes, Alexander Aleshin, Martin Indarte, Ricardo G Correa, Laurie A Bankston, Fabiana I A L Layng, Zamal Ahmed, Ignacio Wistuba, Yong Yao and 7 more

Open access · greenAbstract read
In one paragraph

Article in Experimental cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Role ofJournal of thoracic disease · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Hei-Cheul JeungMD Anderson Cancer Center, Houston, TX, USA; Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-Gu, Seoul, South Korea.
Roisin PuentesSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Alexander AleshinSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Martin IndartePHusis Therapeutics, La Jolla, CA, USA.
Ricardo G CorreaSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Laurie A BankstonSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Fabiana I A L LayngSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Zamal AhmedMD Anderson Cancer Center, Houston, TX, USA.
Ignacio WistubaMD Anderson Cancer Center, Houston, TX, USA.
Yong YaoSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Daniela G DuenasSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Shuxing ZhangMD Anderson Cancer Center, Houston, TX, USA.
Emmanuelle J MeuilletPHusis Therapeutics, La Jolla, CA, USA.
Francesca MarassiSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Robert C LiddingtonSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA.
Lynn KirkpatrickPHusis Therapeutics, La Jolla, CA, USA.
Garth PowisSanford Burnham Prebys Medical Discovery Institute Cancer Center, La Jolla, CA, USA; PHusis Therapeutics, La Jolla, CA, USA. Electronic address: gpowis@phusistherapeutics.com.
Sanford Burnham Prebys Medical Discovery Institute · USThe University of Texas MD Anderson Cancer Center · USPhusis Therapeutics (United States) · US

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2M
Membrane Protein Effectors of Pathogen Interactions With HostR35GM118186 · NIGMS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Francesca M Marassi · 2016 to 2026
$8.5M
Inhibiting Multi-Functional ALDOA for Cancer TherapyR01CA216424 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI POWIS, GARTH · 2018 to 2022
$2.9M
Inhibiting oncogenic KRAS for cancer therapyR01CA160398 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI POWIS, GARTH · 2012 to 2016
$1.9M
Oncogene Addiction Biomarkers for a KRAS TherapyR21CA201707 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI POWIS, GARTH · 2016 to 2017
$467k
(PQD4) MicroRNA Dysregulation in Field Effect is a Prerequisite for TumorigenesisR21CA185504 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI YANG, ZENG-JIE · 2014 to 2015
$427k
NCI NIH HHS P30 CA030199NCI NIH HHS R01 CA160398NCI NIH HHS R01 CA216424NCI NIH HHS R21 CA185504NCI NIH HHS R21 CA201707NIGMS NIH HHS R35 GM118186
6 · The paper itself

Abstract

Plekha7 (Pleckstrin homology [PH] domain containing, family A member 7) regulates the assembly of proteins of the cytoplasmic apical zonula adherens junction (AJ), thus ensuring cell-cell adhesion and tight-junction barrier integrity. Little is known of Plekha7 function in cancer. In colorectal cancer (CRC) Plekha7 expression is elevated compared to adjacent normal tissue levels, increasing with clinical stage. Plekha7 was present at plasma membrane AJ with wild-type KRas (wt-KRas) but was dispersed in cells expressing mutant KRas (mut-KRas). Fluorescence lifetime imaging microscopy (FLIM) indicated a direct Plekha7 interaction with wt-KRas but scantily with mut-KRas. Inhibiting Plekha7 specifically decreased mut-KRas cell signaling, proliferation, attachment, migration, and retarded mut-KRAS CRC tumor growth. Binding of diC8-phosphoinositides (PI) to the PH domain of Plekha7 was relatively low affinity. This may be because a D175 amino acid residue plays a "sentry" role preventing PI(3,4)P

Indexed as

Gene Expression Regulation, NeoplasticMutationApoptosisBiomarkers, TumorCarrier ProteinsCell AdhesionCell ProliferationColorectal NeoplasmsHumansIntercellular JunctionsProto-Oncogene Proteins p21(ras)Signal TransductionTight JunctionsTumor Cells, CulturedBiomarkers, TumorCarrier ProteinsKRAS protein, humanPLEKHA7 protein, humanProto-Oncogene Proteins p21(ras)Mutant KRASPH domainPLEKHA7

Identifiers

PMID34800542
PMCPMC8925131
OpenAlexW3212883975

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.